- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
2024’s Biggest Marketing Stories
Point of care messaging and AI resulted in more targeted campaigns over the past year.
Stock.adobe.com
Emerging Trends at the Intersection of AI & Marketing
In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about what's coming marketing with the use of AI.
From Identity to Margin: Securing Audience Measurement in Pharma Marketing
The industry must find a way to balance consumer privacy and a return on investment in pharma marketing.
Point of care messaging offers unique advantages in pharmaceutical marketing and should be a high priority in brand strategy discussions.
Thursday Night DTC Marketing: Q&A with Dan Switzer
Daiichi Sankyo’s head of US oncology business discusses the company’s first DTC television campaign for Enhertu.
Bringing Marketing to a New Audience: Q&A with Jeremy Truxal
Truxal discusses Exact Science’s first Spanish language TV commercial and campaign for Cologuard.
Using AI and Advanced Analytics Tools to Optimize Marketing Strategies
In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member discusses how CMOs can leverage artificial intelligence and other advanced analytics tools to extract meaningful insights and optimize marketing strategies.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
